Skip to main content
OpenTrials

Clinical trial condition

Retroviridae Infections

Explore clinical trials studying Retroviridae Infections. Study availability and eligibility vary by location and protocol.

5,667 public trials 309 recruiting studies
Refine in advanced search Browse all conditions

Retroviridae Infections trial results

Completed

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations
  • USC CRS Los Angeles, California, United States
  • UCLA CARE Center CRS Los Angeles, California, United States
  • Ucsf Aids Crs San Francisco, California, United States
  • Harbor - UCLA Med. Ctr. CRS Torrance, California, United States
View all 26 locations
View Trial Details
Completed

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

NCT00905489

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • 1100.1518.0001 Boehringer Ingelheim Investigational Site Washington D.C., District of Columbia, United States
  • 1100.1518.0002 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States
  • 1100.1518.2605 Boehringer Ingelheim Investigational Site Francistown, Botswana
  • 1100.1518.2601 Boehringer Ingelheim Investigational Site Gaborone, Botswana
View Trial Details
Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

NCT01328041

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 89 locations
View Trial Details
Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01495702

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +13 more
Locations
  • Spectrum Medical Group Phoenix, Arizona, United States
  • AHF Research Center Beverly Hills, California, United States
  • Pacific Oak Medical Group Beverly Hills, California, United States
  • Kaiser Permanente Hayward, California, United States
View all 80 locations
View Trial Details

Related conditions